NCT05479045 2026-03-16
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Georgetown University
Phase 2 Not yet recruiting
Clinical Trials
90 trialsNCT07455071 2026-03-16
YS247
Peking University Third Hospital
Phase NA Not yet recruiting
NCT07462468 2026-03-13
A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
WestVac Biopharma Co., Ltd.
Phase 1 Not yet recruiting
NCT07469202 2026-03-13
CYTALUX Dose Extension Study
On Target Laboratories, LLC
Phase 4 Not yet recruiting
NCT07465133 2026-03-11
EORTC QOL-OV39
Helios University Hospital Wuppertal
Not yet recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07454018 2026-03-06
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07446049 2026-03-03
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT07406087 2026-02-25
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Kaiser Permanente
Phase NA Not yet recruiting
NCT07429799 2026-02-24
An Exploratory Study of Detection of Endometrial and Ovarian Cancers in Vaginal Samples Retrieved by the Ellele Sampling Device
Ellele Health
Phase NA Not yet recruiting
NCT07389239 2026-02-20
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
Phase 1/2 Not yet recruiting
NCT07420010 2026-02-19
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT07407452 2026-02-12
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Not yet recruiting
NCT07401654 2026-02-10
The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07382479 2026-02-05
NACT-KELIM ID
Aristotle University Of Thessaloniki
Phase NA Not yet recruiting
NCT07385976 2026-02-04
The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients
Far Eastern Memorial Hospital
Not yet recruiting
NCT07387263 2026-02-04
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Unity Health Toronto
Phase NA Not yet recruiting
NCT07382713 2026-02-03
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07286162 2026-01-27
CALM-TF
University Health Network, Toronto
Phase 3 Not yet recruiting
NCT07370818 2026-01-27
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
Onconic Therapeutics Inc.
Phase 2 Not yet recruiting
NCT07362147 2026-01-23
Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life
Taipei Veterans General Hospital, Taiwan
Phase NA Not yet recruiting
NCT07355010 2026-01-21
A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT07340164 2026-01-14
TROY
Yonsei University
Phase 2 Not yet recruiting
NCT07321730 2026-01-07
Visual-PC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Not yet recruiting
NCT07090109 2025-12-31
PITCH - Impacting Hereditary Cancer Testing
University of Kentucky
Phase NA Not yet recruiting
NCT07286266 2025-12-16
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT07271914 2025-12-09
PONDER
Ospedale Santa Croce-Carle Cuneo
Phase NA Not yet recruiting
NCT07273396 2025-12-09
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
Seoul National University Hospital
Phase 1/2 Not yet recruiting
NCT07269574 2025-12-08
Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance
Tongji Hospital
Not yet recruiting
NCT07267780 2025-12-05
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
National Cancer Institute, Naples
Not yet recruiting
NCT07057167 2025-11-20
PANtHer-AI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Not yet recruiting
NCT07239622 2025-11-20
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07219238 2025-10-21
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
Phase 2/3 Not yet recruiting
NCT07168083 2025-09-11
Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting
NCT07160010 2025-09-08
COSMOS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Not yet recruiting
NCT07153705 2025-09-04
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
Shandong University
Not yet recruiting
NCT07117877 2025-08-28
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07146919 2025-08-28
ANGELICA
Centre Leon Berard
Phase 1/2 Not yet recruiting
NCT07070973 2025-08-11
HEMOPEC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Not yet recruiting
NCT07088588 2025-07-28
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1 Not yet recruiting
NCT07068464 2025-07-16
ICRA
NHS Grampian
Phase 3 Not yet recruiting
NCT07044349 2025-06-30
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT06602063 2025-06-27
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
Phase 1/2 Not yet recruiting
NCT06139783 2025-06-25
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Oncare Madrid
Phase NA Not yet recruiting
NCT07031908 2025-06-22
MISSION-2
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Not yet recruiting
NCT07028229 2025-06-19
Ultra-teaching
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Not yet recruiting
NCT07000344 2025-06-02
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Peking Union Medical College Hospital
Phase NA Not yet recruiting
NCT06990503 2025-05-25
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
Tongji Hospital
Phase 3 Not yet recruiting